About Sanofi/Novartis litigation On March 30,2022 ... and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and ...

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers of multiple sclerosis progression.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The quest to understand and slow disease ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader ... The study was supported by Sanofi.

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

For Sanofi, notable drugs like the multiple sclerosis treatment Aubagio have recently lost patent protection. To mitigate the ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

They finished the night far from it. After revealing that Steph Curry will miss multiple games and that Andrew Wiggins has suffered a back strain, the team has another guard injured. The Warriors ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi SAN1.67%increase; green up pointing triangle reported third-quarter earnings and sales that beat analysts’ expectations, boosted by earlier-than-anticipated deliveries of flu and ...